Envestnet Asset Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Envestnet Asset Management’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-104	Closed	-$2K	–	2906
2018 Q2	$2K	Hold	104	–	–	﹤0.01%	2772
2018 Q1	$2K	Buy	104 +52	+100%	+$1.01K	﹤0.01%	2744
2017 Q4	$1K	Hold	52	–	–	﹤0.01%	2941
2017 Q3	$2K	Buy	52 +25	+93%	+$785	﹤0.01%	2829
2017 Q2	$1K	Sell	27 -201	-88%	-$6.27K	﹤0.01%	3021
2017 Q1	$8K	Sell	228 -775	-77%	-$34.2K	﹤0.01%	2830
2016 Q4	$50K	Sell	1,003 -55	-5%	-$2.89K	﹤0.01%	2449
2016 Q3	$56K	Buy	1,058 +11	+1%	+$525	﹤0.01%	2560
2016 Q2	$43K	Buy	+1,047	New	+$45.5K	﹤0.01%	2787

Other funds holding FPRX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Envestnet Asset Management's FPRX Position: Q3 2018 in Review

Envestnet Asset Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q3 2018, closing a stake of 104 shares — an estimated $2K sold.

Envestnet Asset Management first reported a position in FPRX in Q2 2016 and held it in 9 quarters. The position peaked at $56K in Q3 2016. 114 funds tracked by Wall St. Rank hold FPRX as of Q3 2018.

Envestnet Asset Management reported no remaining Five Prime Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
Envestnet Asset Management sold 104 Five Prime Therapeutics, Inc. shares in Q3 2018, an estimated $2K.
Envestnet Asset Management first reported a position in Five Prime Therapeutics, Inc. in Q2 2016 and held it in 9 quarters.
Envestnet Asset Management's Five Prime Therapeutics, Inc. position peaked at $56K in Q3 2016.
114 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q3 2018.

Based on Envestnet Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.